Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZX2021
- Development stage
- Unknown
- Lead developer
- Jiangsu Zhongxin Pharmaceutical
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
ZX2021 is a long-acting, dual-target agonist of the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors. Developed by Jiangsu Zhongxin Pharmaceutical, the drug is designed to treat metabolic disorders, specifically obesity and overweight. By co-activating GLP-1 and GIP receptors, ZX2021 leverages the synergistic effects of these incretin hormones to regulate blood glucose levels, delay gastric emptying, and suppress appetite, leading to significant weight reduction. It is currently undergoing Phase Ib/IIa clinical trials in China, demonstrating potential as a next-generation treatment for chronic weight management.
02
Targets
Beyond the preview
Go deeper on ZX2021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZX2021.